Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division Memorial Sloan-Kettering Cancer Center New York, New York		Maureen Major, RN, MS Clinical Nurse Specialist Evelyn H Lauder Breast Center Memorial Sloan-Kettering Cancer Center New York, New York
	John Mackey, MD Medical Oncologist, Cross Cancer Institute Associate Professor of Oncology University of Alberta Chair, Northern Alberta Breast Cancer Program Director, Cancer International Research Group Edmonton, Canada

CONTENT VALIDATION AND DISCLOSURES

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr Hudis — Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Kosan Biosciences, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc; Ownership Interest: Genomic Health Inc. Dr Mackey — Consulting Fees and Speaking Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Ms Major— Speakers Bureau: Abraxis Oncology, Amgen Inc, Genentech BioOncology.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

The following PIM clinical content reviewers, Jan Hixon, RN; Linda Graham, RN; and Trace Hutchison, PharmD, state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CNE activity of any amount during the past 12 months.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology or Genomic Health Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.